More ARGX headlines
9 articlesArgenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
These Analysts Boost Their Forecasts On Argenx
Argenx says efgartigimod met main goal in myositis trial
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx to buy Forte Biosciences for about $2.2 billion
Latest story Refreshed every 5 minutes; wire stories every 15 minutesAbout this data
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
